Travere Therapeutics, Inc. (TVTX): Price and Financial Metrics


Travere Therapeutics, Inc. (TVTX): $20.01

-0.07 (-0.35%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TVTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

TVTX POWR Grades

  • Value is the dimension where TVTX ranks best; there it ranks ahead of 72.39% of US stocks.
  • The strongest trend for TVTX is in Momentum, which has been heading up over the past 178 days.
  • TVTX's current lowest rank is in the Growth metric (where it is better than 8.79% of US stocks).

TVTX Stock Summary

  • TVTX's price/sales ratio is 5.88; that's higher than the P/S ratio of 80.47% of US stocks.
  • With a year-over-year growth in debt of 82.22%, TRAVERE THERAPEUTICS INC's debt growth rate surpasses 86.32% of about US stocks.
  • Revenue growth over the past 12 months for TRAVERE THERAPEUTICS INC comes in at -3.54%, a number that bests merely 19.85% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to TRAVERE THERAPEUTICS INC, a group of peers worth examining would be TDUP, FBIO, HCWB, APM, and OVID.
  • Visit TVTX's SEC page to see the company's official filings. To visit the company's web site, go to www.retrophin.com.

TVTX Valuation Summary

  • TVTX's price/sales ratio is 6; this is 20% higher than that of the median Healthcare stock.
  • TVTX's EV/EBIT ratio has moved down 4.8 over the prior 121 months.

Below are key valuation metrics over time for TVTX.

Stock Date P/S P/B P/E EV/EBIT
TVTX 2022-12-02 6.0 12.8 -4.9 -6.2
TVTX 2022-12-01 5.9 12.5 -4.7 -6.0
TVTX 2022-11-30 6.1 12.8 -4.9 -6.2
TVTX 2022-11-29 5.7 12.1 -4.6 -5.9
TVTX 2022-11-28 5.7 12.1 -4.6 -5.9
TVTX 2022-11-25 5.9 12.4 -4.7 -6.0

TVTX Growth Metrics

    The 4 year price growth rate now stands at -23.02%.
  • The year over year net income to common stockholders growth rate now stands at 9.78%.
  • The 4 year revenue growth rate now stands at 37.39%.
Over the past 70 months, TVTX's revenue has gone up $79,808,000.

The table below shows TVTX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 213.399 -158.528 -264.232
2022-06-30 228.12 -86.94 -230.215
2022-03-31 228.57 -43.638 -202.195
2021-12-31 227.49 -14.792 -180.091
2021-09-30 221.224 -1.785 -250.14
2021-06-30 204.146 -27.113 -237.05

TVTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TVTX has a Quality Grade of C, ranking ahead of 60.91% of graded US stocks.
  • TVTX's asset turnover comes in at 0.306 -- ranking 150th of 681 Pharmaceutical Products stocks.
  • VTVT, FBRX, and NATR are the stocks whose asset turnover ratios are most correlated with TVTX.

The table below shows TVTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.306 0.969 -0.399
2021-06-30 0.291 0.968 -0.396
2021-03-31 0.289 0.968 -0.412
2020-12-31 0.311 0.969 -0.361
2020-09-30 0.304 0.970 -0.166
2020-06-30 0.303 0.967 -0.194

TVTX Price Target

For more insight on analysts targets of TVTX, see our TVTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $32.71 Average Broker Recommendation 1.25 (Strong Buy)

TVTX Stock Price Chart Interactive Chart >

Price chart for TVTX

TVTX Price/Volume Stats

Current price $20.01 52-week high $31.65
Prev. close $20.08 52-week low $18.70
Day low $19.69 Volume 645,609
Day high $20.33 Avg. volume 756,744
50-day MA $22.06 Dividend yield N/A
200-day MA $24.68 Market Cap 1.28B

Travere Therapeutics, Inc. (TVTX) Company Bio


Travere Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on identifying, developing, and delivering therapies to people living with rare disease. Travere Therapeutics serves customers worldwide.


TVTX Latest News Stream


Event/Time News Detail
Loading, please wait...

TVTX Latest Social Stream


Loading social stream, please wait...

View Full TVTX Social Stream

Latest TVTX News From Around the Web

Below are the latest news stories about TRAVERE THERAPEUTICS INC that investors may wish to consider to help them evaluate TVTX as an investment opportunity.

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on November 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 173,000 shares of its common stock to 12 new employees, consisting of inducement stock options to purchase an aggregate of 90,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 83,000 shares of its common stock

Yahoo | November 16, 2022

Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease

Developed in collaboration with the rare kidney disease community, RKD & Me aims to amplify the experiences of people living with rare kidney disease. SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., the IgA Nephropathy Foundation, and NephCure Kidney International today announced the launch of RKD & Me, a new public awareness campaign that spotlights the real stories of people living with rare kidney disease to amplify their unique lived experiences, educate the public,

Yahoo | November 15, 2022

Travere Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences: Jefferies 2022 London Healthcare ConferenceWednesday, November 16, 2022, at 4:25 p.m. GMT (11:25 a.m. ET) 5th Annual Evercore ISI HealthCONx ConferenceTuesday, November 29, 2022, at 1:25 p.m. ET Piper Sandler Healthcare ConferenceThursday, December 1, 2022, at 10:30 a.m. ET BofA Securities 2022 Biotech SMID Cap Conf

Yahoo | November 9, 2022

Analysts Offer Insights on Healthcare Companies: Chimerix (CMRX), Travere Therapeutics (TVTX) and Karuna Therapeutics (KRTX)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Chimerix (CMRX – Research Report), Travere Therapeutics (TVTX – Research Report) and Karuna Therapeutics (KRTX – Research Report) with bullish sentiments. Chimerix (CMRX) JonesTrading analyst Soumit Roy reiterated a Buy rating on Chimerix today and set a price target of $5.00. The company's shares closed last Thursday at $1.86, close to its 52-week low of $1.27. According to TipRanks.

Brian Anderson on TipRanks | November 3, 2022

Travere Therapeutics Reports Third Quarter 2022 Financial Results

EMA accepted for review the Conditional Marketing Authorization application for sparsentan for IgAN in Europe; review decision expected in second half of 2023 New PDUFA target action date for sparsentan in IgAN set for February 17, 2023 Net product sales of $50.8 million for the third quarter of 2022 SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its third quarter 2022 financial results and provided a corporate update. European Medicines Age

Yahoo | October 27, 2022

Read More 'TVTX' Stories Here

TVTX Price Returns

1-mo -3.61%
3-mo -22.41%
6-mo -12.92%
1-year -27.53%
3-year 50.90%
5-year N/A
YTD -35.53%
2021 13.89%
2020 91.94%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7004 seconds.